Vetter Pharma manufacturing site in Germany plans have been confirmed as the pharmaceutical service provider moves forward with building a new commercial production facility in the Saarland region of southwest Germany. The company said construction is scheduled to begin in the second quarter of 2026, with operations expected to start in 2031.
The investment in the new site is a key element of the company’s long-term growth strategy. The first phase of construction will cost around €480 million. The contract development and manufacturing organization is acquiring a 95-acre industrial site in Saarlouis, which it bought at the end of 2024 following a comprehensive site selection process. Up to €47 million in state aid has been approved by the European Commission for the project. The development could create up to 2,000 jobs in the long term.
“With the construction of our new production facility in Germany, we continue on our path to sustainable growth. Long-term success derives from striking the right balance between stability and expansion,” emphasizes Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family. “With our investments in the state of Saarland, only a five hour drive away from our headquarters in Ravensburg, we are strengthening our commitment to Germany’s economic landscape while reaffirming our engagement as a strategic partner to the global pharmaceutical market.”
Alongside the Vetter Pharma manufacturing site in Germany, the company is also expanding its footprint internationally. Construction of another new clinical production facility has already started, this time in Des Plaines, Illinois. It will enable aseptic production to support early-phase clinical trials.
Vetter has over 75 years of experience in sterile manufacturing of pharmaceuticals. The company continues to invest in Germany, Austria and the United States to expand its capacity for production in response to growing customer demand. The new facility in Saarland will substantially increase capacity for the production of injectable drugs and further strengthen Vetter’s role in the global supply of pharmaceuticals.
